ReviewEuropean respiratory review : an official journal of the European Respiratory Society2015
Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences.
Review in European respiratory review : an official journal of the European Respiratory Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- New analogs of 5-substituted-2(1Acta biochimica Polonica · 2025Article
- Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.Biotech (Basel (Switzerland)) · 2023Review
- Low Molecular Weight Fucoidan Inhibits Pulmonary Fibrosis In Vivo and In Vitro via Antioxidant Activity.Oxidative medicine and cellular longevity · 2022Article
- The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities.Internal and emergency medicine · 2021Observational
- Human pluripotent stem-cell-derived alveolar organoids for modeling pulmonary fibrosis and drug testing.Cell death discovery · 2021Article
- Observational
- Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue.European respiratory review : an official journal of the European Respiratory Society · 2019Review
- Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.PharmacoEconomics · 2019Review
- Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.Advances in therapy · 2019Review
- Cell-based therapy for idiopathic pulmonary fibrosis.Stem cell investigation · 2019Review
- Randomised controlled trials and real-life studies: two answers for one question.European respiratory review : an official journal of the European Respiratory Society · 2018Article
- A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.Proteomics. Clinical applications · 2018Article
- Severe idiopathic pulmonary fibrosis: what can be done?European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Role of pirfenidone in the management of pulmonary fibrosis.Therapeutics and clinical risk management · 2017Review
- Article
- Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis.Physiological reports · 2016Article
- Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results.European clinical respiratory journal · 2016Article
- Article
- A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study.European clinical respiratory journal · 2016Article
- Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?European respiratory review : an official journal of the European Respiratory Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomised controlled clinical trials are fundamental in medicine to develop new effective drugs and new therapeutic regimens and are the strength of evidence-based medicine. These studies allow us to avoid the repetition of misleading experiences that have been reported in the past, where drugs or associations were utilised without compelling evidence and ultimately proven to be ineffective. In recent years, randomised clinical trials have been conducted and concluded for many rare diseases, including idiopathic pulmonary fibrosis. However, clinical trials do not always reflect the real-life scenario. Patients selected for clinical trials present fewer comorbidities, they fall between certain age limits, and the severity of their disease is defined; therefore, they do not always reflect the whole of the population affected by a specific disease. These are the reasons why we also need data that mirror real-life experience. The limitations that these kind of studies present are always several and the studies should be interpreted with caution, although they can fill the important gap between efficacy and effectiveness. In this article, we will review the existing clinical data on real-life treatment of idiopathic pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.